A Signal Finding Phase 2 Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) and Relatlimab (Anti-LAG-3 Monoclonal Antibody; BMS-986016) in Patients With Advanced Chordoma
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- 05 Apr 2019 Planned End Date changed from 12 Jul 2022 to 3 Apr 2022.
- 05 Apr 2019 Planned primary completion date changed from 31 Aug 2021 to 3 Apr 2021.
- 05 Apr 2019 Status changed from not yet recruiting to recruiting.